<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lantheus Holdings Inc — News on 6ix</title>
<link>https://6ix.com/company/lantheus-holdings-inc</link>
<description>Latest news and press releases for Lantheus Holdings Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lantheus-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683592d578dffbe2df1030bd.webp</url>
<title>Lantheus Holdings Inc</title>
<link>https://6ix.com/company/lantheus-holdings-inc</link>
</image>
<item>
<title>Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-to-host-first-quarter-2026-earnings-conference-call-and-webcast-on-may-7-2026-at-800-am-eastern-time</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-to-host-first-quarter-2026-earnings-conference-call-and-webcast-on-may-7-2026-at-800-am-eastern-time</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>BEDFORD, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 7, 2026, to discuss its financial results and provide a business update for the first quarter of 2026. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to regis</description>
</item>
<item>
<title>Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-three-month-extension-of-pdufa-date-for-lnth-2501-ga-68-edotreotide-a-pet-diagnostic-imaging-kit-targeting-somatostatin-receptor-positive-sstr-neuroendocrine-tumors-nets</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-three-month-extension-of-pdufa-date-for-lnth-2501-ga-68-edotreotide-a-pet-diagnostic-imaging-kit-targeting-somatostatin-receptor-positive-sstr-neuroendocrine-tumors-nets</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused</description>
</item>
<item>
<title>Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-approval-of-pylarify-truvutm-piflufolastat-f-18-injection-4</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-approval-of-pylarify-truvutm-piflufolastat-f-18-injection-4</guid>
<pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
<description>New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the</description>
</item>
<item>
<title>Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-receives-fda-tentative-approval-for-lutetium-lu-177-dotatate-pnt2003-radioequivalent-to-lutatherar</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-receives-fda-tentative-approval-for-lutetium-lu-177-dotatate-pnt2003-radioequivalent-to-lutatherar</guid>
<pubDate>Mon, 02 Mar 2026 13:30:00 GMT</pubDate>
<description>BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has received U.S. Food and Drug Administration (FDA) tentative approval for the Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent1 version of LUTATHERA® (lu</description>
</item>
<item>
<title>Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for</description>
</item>
<item>
<title>Lantheus to Present at March 2026 Investor Conferences</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-to-present-at-march-2026-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-to-present-at-march-2026-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences. TD Cowen 46th Annual Health Care ConferenceMarch 3, 2026 at 11:10 a.m. ETLeerink Global Healthca</description>
</item>
<item>
<title>Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-host-fourth-quarter-full-130000340</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-host-fourth-quarter-full-130000340</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to r</description>
</item>
<item>
<title>Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-closing-spect-business-sale-shine-technologies-2026-01-02</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-closing-spect-business-sale-shine-technologies-2026-01-02</guid>
<pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
<description>BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading</description>
</item>
<item>
<title>Lantheus to Present Florbetaben F 18 Data at CTAD 2025</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-present-florbetaben-f-18-data-ctad-2025-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-present-florbetaben-f-18-data-ctad-2025-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company</description>
</item>
<item>
<title>Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of</description>
</item>
<item>
<title>Lantheus Announces Leadership Transition Plan</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-leadership-transition-plan-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-leadership-transition-plan-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company’s Strategy to be Led by Prior CEO</description>
</item>
<item>
<title>Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-grants-pdufa-date-lnth-2501-ga-68-edotreotide-pet-diagnostic</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-grants-pdufa-date-lnth-2501-ga-68-edotreotide-pet-diagnostic</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>PDUFA Date Set for March 29, 2026 BEDFORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading</description>
</item>
<item>
<title>Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-acceptance-new-drug-application-mk-6240-pet-imaging-agent</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-acceptance-new-drug-application-mk-6240-pet-imaging-agent</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>PDUFA Date Set for August 13, 2026 BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading</description>
</item>
<item>
<title>Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-host-third-quarter-2025-earnings-conference-call-and-webcast-november-6-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-host-third-quarter-2025-earnings-conference-call-and-webcast-november-6-2025</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call</description>
</item>
<item>
<title>Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-and-ge-healthcare-announce-exclusive-licensing-agreement-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-and-ge-healthcare-announce-exclusive-licensing-agreement-prostate-cancer</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today</description>
</item>
<item>
<title>Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-present-morgan-stanley-23rd-annual-global-healthcare-conference-2025-09-02</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-present-morgan-stanley-23rd-annual-global-healthcare-conference-2025-09-02</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company</description>
</item>
<item>
<title>Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-reports-second-quarter-2025-110000364</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-reports-second-quarter-2025-110000364</guid>
<pubDate>Wed, 06 Aug 2025 11:00:00 GMT</pubDate>
<description>Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18</description>
</item>
<item>
<title>Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-acceptance-nda-new-formulation-market-leading-psma-pet-imaging</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-announces-fda-acceptance-nda-new-formulation-market-leading-psma-pet-imaging</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026</description>
</item>
<item>
<title>Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-host-second-quarter-2025-earnings-conference-call-and-webcast-august-6-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-host-second-quarter-2025-earnings-conference-call-and-webcast-august-6-2025</guid>
<pubDate>Wed, 23 Jul 2025 04:00:00 GMT</pubDate>
<description>BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call</description>
</item>
<item>
<title>Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D</title>
<link>https://6ix.com/company/lantheus-holdings-inc/news/lantheus-completes-acquisition-life-molecular-imaging-and-appoints-dr-ludger</link>
<guid isPermaLink="true">https://6ix.com/company/lantheus-holdings-inc/news/lantheus-completes-acquisition-life-molecular-imaging-and-appoints-dr-ludger</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful</description>
</item>
</channel>
</rss>